Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis.
Yoon-Koo KangShukui QinKeun-Wook LeeSang Cheul OhIn-Ho KimJong Gwang KimYong LiZhuchen YanJin LiLi-Yuan BaiCatherine ChanAkeem YusufAnita Zahlten-KümeliKate TaylorKensei YamaguchiPublished in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2024)
In East Asian patients with FGFR2b-positive advanced/metastatic G/GEJC enrolled in the global FIGHT study, bemarituzumab-mFOLFOX6 showed clinically meaningful outcomes over placebo-mFOLFOX6.
Keyphrases
- phase ii study
- locally advanced
- squamous cell carcinoma
- metastatic colorectal cancer
- small cell lung cancer
- neoadjuvant chemotherapy
- rectal cancer
- papillary thyroid
- radiation therapy
- open label
- phase iii
- squamous cell
- type diabetes
- double blind
- randomized controlled trial
- metabolic syndrome
- clinical trial
- adipose tissue
- insulin resistance
- young adults
- study protocol